You may stop thinking so much about food with Tirzepatide. The drug acts like meal hormones called GIP and GLP-1.
Your scale and blood tests can change during treatment. Knowing the benefits and harms helps you prepare for your medical visit.
Hunger can fade as treatment lowers raised sugar
You might finish a meal without thinking about the next. Tirzepatide treats obesity and type 2 diabetes with a prescription.
May 2022 brought diabetes approval, followed by weight approval in November 2023. Approval also covers sleep apnea (breathing that keeps stopping during sleep).
The drug joins 39 amino acids (parts joined to form proteins). A short chain made from those protein parts is a peptide.
Tirzepatide acts like meal hormones called GIP and GLP-1. Hormones carry instructions through your body, rather like your morning mail.
Those actions help release insulin, which lets your cells use sugar. Your hunger can ease, but your response isn't assured.
Earlier medicines used only the action of the meal hormone GLP-1. Tirzepatide brought the larger improvements in both sugar and weight.
A large phase 3 study checked benefits and harms in 2539 adults. Called SURMOUNT-1, the study lasted 72 weeks [4].
At 15 mg, the average loss reached 20.9% of original weight. That's roughly a fifth, though your loss could differ.
Upset stomachs often troubled people while researchers increased the treatment amounts. Comfort matters alongside the changes in your weight and sugar.
The effects page explains people's experiences and the treatment warnings. You can follow each study number to its published paper.
The Tirzepatide peptide (a protein chain) lasts for days
Your body doesn't clear the medicine straight after the shot. Five days later, roughly half still remains [1].
Early studies called tirzepatide LY3298176, so both names mean one drug. The medicine is a 39-amino-acid chain (small protein parts joined together).
Scientists used a meal hormone, GIP, as the starting design. They added a small fat part to the medicine itself.
That added part lets a blood protein carry the drug. While attached, the medicine leaves your body more slowly.
After eating, your gut releases hormones called GIP and GLP-1. Both help your pancreas, an insulin-making gland, release more insulin.
GIP helps that release when your sugar has gone up. GLP-1 also curbs a sugar-raising hormone and slows stomach emptying.
Your stomach doesn't empty food as quickly, which can ease hunger. Tirzepatide combines both hormone actions in one medicine [1].
First, scientists tested cells in dishes, rather than treating people. They measured a chemical response inside cells that prompts insulin release.
Tirzepatide strengthened that response more through GIP than GLP-1. The test didn't measure changes in hunger or weight.
Cells have proteins on their surface where these hormones attach. A cell can pull those proteins inward, away from its surface.
Tirzepatide left more attachment proteins outside than natural GLP-1 did [2]. More outside could keep insulin release going, but doesn't prove your benefit.
Researchers then tested human pancreas cells taken out of the body. Blocking GIP's attachment reduced the insulin those cells released with tirzepatide [11].
Tirzepatide results included less weight and lower sugar
Adults with obesity lost weight during the study called SURMOUNT-1. Researchers followed 2539 adults without diabetes during a 72-week study.
The phase 3 study wasn't checking weight loss alone. Weekly amounts were 5 mg, 10 mg and 15 mg.
Average losses were 15.0%, 19.5% and 20.9% of starting weight [4]. Placebo (shots without medicine) brought a loss of 3.1%.
So the larger amounts brought larger losses in those groups. Your own loss can't be read straight from those averages.
Entry depended on a score using weight and height. People qualified at 30, or at 27 with a related illness.
The score rises as your weight increases for your height. Your doctor can explain your score.
Semaglutide, another diabetes and weight medicine, was the comparison in SURMOUNT-5. That 72-week study treated 751 adults with obesity [5].
People lost 20.2% of starting weight with tirzepatide, versus 13.7% with semaglutide. More tirzepatide users reached losses of 10%, 15% or 20%.
These percentages describe weight lost, not the number of people helped. Those results can't guarantee your weight loss.
Researchers also studied type 2 diabetes in the SURPASS studies. SURPASS-2 compared treatments in 1879 adults during a 40-week phase 3 study.
Their three-month sugar blood test gives a reading as a percentage. Tirzepatide lowered that reading by 2.01, 2.24 and 2.30 percentage points [3].
Those falls matched 5 mg, 10 mg and 15 mg. Subtract the fall from the starting percentage to get the later reading.
The comparison medicine lowered the same reading by 1.86 percentage points. Weight fell further with tirzepatide in that study too [3].
A review brought together 6 studies with 6,579 people [12]. Higher amounts generally helped more, without clearly increasing low-sugar risk when used alone.
Your own illnesses affect how your doctor judges these findings. Tirzepatide research describes more of the people and treatments studied.
Tirzepatide vs semaglutide showed a larger drop in weight
Semaglutide, another diabetes and weight medicine, was the comparison in SURMOUNT-5. Researchers followed 751 adults with obesity during 72 weeks [5].
Losses averaged 20.2% of starting weight with tirzepatide, versus 13.7% with semaglutide. Waists shrank more too, but that doesn't settle your choice.
SURPASS-2 studied 1879 adults with diabetes over 40 weeks [3]. Semaglutide at 1 mg didn't improve sugar as much as tirzepatide.
Tirzepatide's added weight losses were 1.9, 3.6 and 5.5 kg. The gaps grew as study amounts rose.
A 2026 review used separate studies testing 50 mg semaglutide pills [13]. Tirzepatide's 10 mg and 15 mg amounts brought larger losses.
Estimated gaps were 4.48% and 5.59% of starting weight. Those aren't either group's total loss.
The 95% range marks likely sizes of that estimated gap. Side effects looked similar, but separate studies aren't direct comparisons for your doctor.
Your past illnesses can rule out this treatment
Your past illnesses matter when weight treatment seems appealing. Approval covers type 2 diabetes from May 2022 and weight care from November 2023.
More severe sleep apnea with obesity is approved too [7]. Sleep apnea repeatedly stops your breathing during sleep.
Your weight-for-height score marks obesity at 30. A score of 27 qualifies with related illness, but doesn't settle your prescription.
Approval doesn't include type 1 diabetes. Related medicines caused thyroid tumors in mice and rats.
The thyroid is your neck's hormone-making gland. Researchers can't establish that animal tumor risk in people.
Certain thyroid cancers in you or relatives prevent use. Multiple Endocrine Neoplasia syndrome type 2 prevents treatment as well [15].
That inherited illness can cause several glands to develop tumors. Nausea, constipation, vomiting and diarrhea often followed treatment increases.
Most complaints weren't severe, though your comfort still matters. A review brought together 9 studies involving 9,871 people [6].
Gallbladder or bile-duct illness risk rose to 1.97 times the comparison risk. Other groups took placebo or other diabetes medicines, including insulin.
That's nearly double, but it doesn't say how common illness was. Their 95% range of likely results supported a rise, not an exact size.
You can't calculate your chance without illness counts for each group. The review didn't establish increased pancreas inflammation.
Tirzepatide effects explains these warnings more fully. Your doctor's choice depends on your health, not just your weight.